Inhibitory effect of terfenadine on Kir2.1 and Kir2.3 channels

Delgado-Ramírez, Mayra; Rodriguez-Leal, Fanny Junue; Rodríguez-Menchaca, Aldo Azmar; Moreno-Galindo, Eloy Gerardo; Sanchez-Chapula, José Antonio; Ferrer, Tania

doi:10.2478/acph-2021-0017

Abstract

Terfenadine is a second-generation H1-antihistamine that despite potentially can produce severe side effects it has recently gained attention due to its anticancer properties. Lately, the subfamily 2 of inward rectifier potassium channels (Kir2) has been implicated in the progression of some tumoral processes. Hence, we characterized the effects of terfenadine on Kir2.x channels expressed in HEK-293 cells. Terfenadine inhibited Kir2.3 channels with a strikingly greater potency (IC₅₀ = 1.06 ± 0.11 μmol L⁻¹) compared to Kir2.1 channels (IC₅₀ = 27.8 ± 4.8 μmol L⁻¹). The Kir2.3(I213L) mutant, possessing a larger affinity for phosphatidylinositol 4,5-bisphosphate (PIP₂) than the wild-type Kir2.3, was less sensitive to terfenadine inhibition (IC₅₀ = 13.0 ± 2.9 μmol L⁻¹). Additionally, the PIP₂ intracellular application had largely reduced the inhibition of Kir2.1 channels by terfenadine. Our data support that Kir2.x channels are targets of terfena-dine by affecting their interaction with PIP₂, which could be regarded as a mechanism of the antitumor properties of terfenadine.

References

1. D. McTavish, K. L. Goa and M. Ferrill, Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy, Drugs39 (1990) 552–574; https://doi.org/10.2165/00003495-199039040-0000610.2165/00003495-199039040-00006
Search in Google Scholar Back to article
2. F. Register, Proposal to withdraw approval of two new drug applications and one abbreviated new drug application; opportunity for a hearing. Food and Drug Administration [Docket No. 96N-0512], Federal Register62 (1997) 2–9.
Search in Google Scholar Back to article
3. T. J. MacConnell and A. J. Stanners, Torsades de pointes complicating treatment with terfenadine, BMJ302 (1991) 1469; https://doi.org/10.1136/bmj.302.6790.1469-b10.1136/bmj.302.6790.1469-b
Search in Google Scholar Back to article
4. K. Kamiya, R. Niwa, M. Morishima, H. Honjo and M. C. Sanguinetti, Molecular determinants of hERG channel block by terfenadine and cisapride, J. Pharmacol. Sci. 108 (2008) 301–307; https://doi.org/10.1254/jphs.08102fp10.1254/jphs.08102FP
Search in Google Scholar Back to article
5. H. R. Lu, A. N. Hermans and D. J. Gallacher, Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?, Br. J. Pharmacol. 166 (2012) 1490–1502; https://doi.org/10.1111/j.1476-5381.2012.01880.x10.1111/j.1476-5381.2012.01880.x
Search in Google Scholar Back to article
6. C. Valenzuela, E. Delpon, L. Franqueza, P. Gay, J. Vicente and J. Tamargo, Comparative effects of nonsedating histamine H1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels, Eur. J. Pharmacol. 326 (1997) 257–263; https://doi.org/10.1016/s0014-2999(97)85421-010.1016/S0014-2999(97)85421-0
Search in Google Scholar Back to article
7. I. S. Chen, C. Liu, M. Tateyama, I. Karbat, M. Uesugi, E. Reuveny and Y. Kubo, Non-sedating antihistamines block G-protein-gated inwardly rectifying K(+) channels, Br. J. Pharmacol. 176 (2019) 3161–3179; https://doi.org/10.1111/bph.1471710.1111/bph.14717669264031116876
Search in Google Scholar Back to article
8. E. Hadzijusufovic, B. Peter, K. V. Gleixner, K. Schuch, W. F. Pickl, T. Thaiwong, V. Yuzbasiyan-Gurkan, I. Mirkina, M. Willmann and P. Valent, H1-receptor antagonists terfenadine and lorata-dine inhibit spontaneous growth of neoplastic mast cells, Exp. Hematol. 38 (2010) 896–907; https://doi.org/10.1016/j.exphem.2010.05.00810.1016/j.exphem.2010.05.008433797120570632
Search in Google Scholar Back to article
9. F. Nicolau-Galmes, A. Asumendi, E. Alonso-Tejerina, G. Perez-Yarza, S. M. Jangi, J. Gardeazabal, Y. Arroyo-Berdugo, J. M. Careaga, J. L. Diaz-Ramon, A. Apraiz and M. D. Boyano, Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms, Apoptosis16 (2011) 1253–1267; https://doi.org/10.1007/s10495-011-0640-y10.1007/s10495-011-0640-y320400121861192
Search in Google Scholar Back to article
10. W. T. Wang, Y. H. Chen, J. L. Hsu, W. J. Leu, C. C. Yu, S. H. Chan, Y. F. Ho, L. C. Hsu and J. H. Guh, Terfenadine induces anti-proliferative and apoptotic activities in human hormone-refractory prostate cancer through histamine receptor-independent Mcl-1 cleavage and Bak up-regulation, Naunyn Schmiedebergs Arch. Pharmacol. 387 (2014) 33–45; https://doi.org/10.1007/s00210-013-0912-x10.1007/s00210-013-0912-x24048439
Search in Google Scholar Back to article
11. P. Fernandez-Nogueira, A. Noguera-Castells, G. Fuster, L. Recalde-Percaz, N. Moragas, A. Lopez-Plana, E. Enreig, P. Jauregui, N. Carbo, V. Almendro, P. Gascon, P. Bragado and M. Mancino, Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer, Cancer Lett. 424 (2018) 70–83; https://doi.org/10.1016/j.canlet.2018.03.01410.1016/j.canlet.2018.03.01429548821
Search in Google Scholar Back to article
12. L. An, D. D. Li, H. X. Chu, Q. Zhang, C. L. Wang, Y. H. Fan, Q. Song, H. D. Ma, F. Feng and Q. C. Zhao, Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal, Pharmacol. Res. 124 (2017) 105–115; https://doi.org/10.1016/j.phrs.2017.07.02110.1016/j.phrs.2017.07.02128754458
Search in Google Scholar Back to article
13. H. Hibino, A. Inanobe, K. Furutani, S. Murakami, I. Findlay and Y. Kurachi, Inwardly rectifying potassium channels: their structure, function, and physiological roles, Physiol. Rev. 90 (2010) 291–366; https://doi.org/10.1152/physrev.00021.200910.1152/physrev.00021.200920086079
Search in Google Scholar Back to article
14. P. Sulaiman, Y. Xu, M. E. Fina, S. R. Tummala, H. Ramakrishnan, A. Dhingra and N. Vardi, Kir2.4 surface expression and basal current are affected by heterotrimeric G-proteins, J. Biol. Chem. 288 (2013) 7420–7429; https://doi.org/10.1074/jbc.M112.41279110.1074/jbc.M112.412791359164923339194
Search in Google Scholar Back to article
15. C. D. Ji, Y. X. Wang, D. F. Xiang, Q. Liu, Z. H. Zhou, F. Qian, L. Yang, Y. Ren, W. Cui, S. L. Xu, X. L. Zhao, X. Zhang, Y. Wang, P. Zhang, J. M. Wang, Y. H. Cui and X. W. Bian, Kir2.1 Interaction with Stk38 promotes invasion and metastasis of human gastric cancer by enhancing MEKK2-MEK1/2-ERK1/2 signaling, Cancer Res. 78 (2018) 3041–3053; https://doi.org/10.1158/0008-5472.CAN-17-377610.1158/0008-5472.CAN-17-3776811178829549164
Search in Google Scholar Back to article
16. H. Liu, J. Huang, J. Peng, X. Wu, Y. Zhang, W. Zhu and L. Guo, Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway, Mol. Cancer14 (2015) 59; https://doi.org/10.1186/s12943-015-0298-010.1186/s12943-015-0298-0437312825880778
Search in Google Scholar Back to article
17. I. Lee, S. J. Lee, T. M. Kang, W. K. Kang and C. Park, Unconventional role of the inwardly rectifying potassium channel Kir2.2 as a constitutive activator of RelA in cancer, Cancer Res. 73 (2013) 1056–1062; https://doi.org/10.1158/0008-5472.CAN-12-249810.1158/0008-5472.CAN-12-249823269273
Search in Google Scholar Back to article
18. X. Y. Wu and X. Y. Yu, Overexpression of KCNJ4 correlates with cancer progression and unfavorable prognosis in lung adenocarcinoma, J. Biochem. Mol. Toxicol. 33 (2019) e22270; https://doi.org/10.1002/jbt.2227010.1002/jbt.2227030512237
Search in Google Scholar Back to article
19. M. A. van der Heyden, A. Stary-Weinzinger and J. A. Sanchez-Chapula, Inhibition of cardiac inward rectifier currents by cationic amphiphilic drugs, Curr. Mol. Med. 13 (2013) 1284–1298; https://doi.org/10.2174/1566524011313999004310.2174/1566524011313999004323448372
Search in Google Scholar Back to article
20. P. Thomas and T. G. Smart, HEK293 cell line: a vehicle for the expression of recombinant proteins, J. Pharmacol. Toxicol. Methods. 51 (2005) 187–200; https://doi.org/10.1016/j.vascn.2004.08.01410.1016/j.vascn.2004.08.01415862464
Search in Google Scholar Back to article
21. X. Du, H. Zhang, C. Lopes, T. Mirshahi, T. Rohacs and D. E. Logothetis, Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of kir channels by diverse modulators, J. Biol. Chem. 279 (2004) 37271–37281; https://doi.org/10.1074/jbc.M40341320010.1074/jbc.M40341320015155739
Search in Google Scholar Back to article
22. S. Przestalski, J. Sarapuk, H. Kleszczynska, J. Gabrielska, J. Hladyszowski, Z. Trela and J. Kuczera, Influence of amphiphilic compounds on membranes, Acta Biochim. Pol. 47 (2000) 627–638.10.18388/abp.2000_3984
Search in Google Scholar Back to article
23. J. J. Babcock and M. Li, hERG channel function: beyond long QT, Acta Pharmacol. Sin. 34 (2013) 329–335; https://doi.org/10.1038/aps.2013.610.1038/aps.2013.6358791523459091
Search in Google Scholar Back to article
24. G. D’Alessandro, M. Catalano, M. Sciaccaluga, G. Chece, R. Cipriani, M. Rosito, A. Grimaldi, C. Lauro, G. Cantore, A. Santoro, B. Fioretti, F. Franciolini, H. Wulff and C. Limatola, KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo, Cell Death Dis. 4 (2013) e773; https://doi.org/10.1038/cddis.2013.27910.1038/cddis.2013.279376344123949222
Search in Google Scholar Back to article
25. M. Nunez, V. Medina, G. Cricco, M. Croci, C. Cocca, E. Rivera, R. Bergoc and G. Martin, Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDAMB-231, BMC Pharmacol. Toxicol. 14 (2013) 6; https://doi.org/10.1186/2050-6511-14-610.1186/2050-6511-14-6355838623311706
Search in Google Scholar Back to article

Inhibitory effect of terfenadine on Kir2.1 and Kir2.3 channels

Abstract

Paradigm

My account